Truist Financial Corp Has $76.78 Million Stock Position in AstraZeneca PLC $AZN

Truist Financial Corp increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 23.0% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,000,772 shares of the company’s stock after purchasing an additional 187,019 shares during the period. Truist Financial Corp’s holdings in AstraZeneca were worth $76,779,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Y Intercept Hong Kong Ltd grew its position in AstraZeneca by 111.6% in the third quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock valued at $5,113,000 after acquiring an additional 35,148 shares during the last quarter. Oxbow Advisors LLC lifted its holdings in shares of AstraZeneca by 96.2% in the third quarter. Oxbow Advisors LLC now owns 77,594 shares of the company’s stock worth $5,953,000 after acquiring an additional 38,043 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of AstraZeneca by 10.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 191,518 shares of the company’s stock valued at $16,156,000 after purchasing an additional 17,548 shares in the last quarter. Voya Investment Management LLC boosted its stake in shares of AstraZeneca by 68.2% in the 3rd quarter. Voya Investment Management LLC now owns 1,899,502 shares of the company’s stock valued at $145,730,000 after purchasing an additional 770,417 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of AstraZeneca during the 3rd quarter valued at approximately $14,884,000. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Morgan Stanley reissued an “overweight” rating and issued a $103.00 price objective on shares of AstraZeneca in a research note on Wednesday, December 3rd. Wall Street Zen cut AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. TD Cowen reissued a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. Finally, Citigroup initiated coverage on AstraZeneca in a research note on Tuesday. They set a “buy” rating on the stock. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Stock Performance

NASDAQ AZN opened at $93.22 on Thursday. The company has a market capitalization of $289.15 billion, a price-to-earnings ratio of 30.97, a PEG ratio of 1.64 and a beta of 0.34. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $96.51. The stock has a fifty day simple moving average of $92.18 and a 200 day simple moving average of $84.08.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The firm had revenue of $15.19 billion for the quarter, compared to analyst estimates of $14.75 billion. During the same quarter in the previous year, the company posted $2.08 EPS. The business’s revenue was up 12.0% on a year-over-year basis. Sell-side analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.